Multivariable analysis of the impact of absolute B-cell count on the individual components of the CLL-IPI in individuals with Rai 0 CLL and MBL
| Characteristic . | Time to first therapy . | Overall survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age >65 y | 0.8 | 0.6-1.1 | .12 | 3.5 | 2.5-4.9 | <.0001 |
| Unmutated IGHV genes | 3.4 | 2.6-4.4 | <.0001 | 1.7 | 1.3-2.3 | .0004 |
| Serum β-2 microglobulin >3.5 g/L | 2.5 | 1.7-3.6 | <.0001 | 2.7 | 1.9-3.7 | <.0001 |
| TP53 disruption | 1.4 | 0.7-2.7 | .36 | 2.2 | 1.3-3.7 | .005 |
| Absolute B-cell count* | 1.31 | 1.26-1.37 | <.0001 | 1.1 | 1.01-1.2 | .02 |
| Rai stage† | NA | NA | NA | NA | NA | NA |
| Characteristic . | Time to first therapy . | Overall survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age >65 y | 0.8 | 0.6-1.1 | .12 | 3.5 | 2.5-4.9 | <.0001 |
| Unmutated IGHV genes | 3.4 | 2.6-4.4 | <.0001 | 1.7 | 1.3-2.3 | .0004 |
| Serum β-2 microglobulin >3.5 g/L | 2.5 | 1.7-3.6 | <.0001 | 2.7 | 1.9-3.7 | <.0001 |
| TP53 disruption | 1.4 | 0.7-2.7 | .36 | 2.2 | 1.3-3.7 | .005 |
| Absolute B-cell count* | 1.31 | 1.26-1.37 | <.0001 | 1.1 | 1.01-1.2 | .02 |
| Rai stage† | NA | NA | NA | NA | NA | NA |
NA, not available.
*HR for each 10 × 109/L increase.
†All individuals would fall in the Rai stage 0 category.